

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 03/057220 A1

(51) International Patent Classification⁷: A61K 31/4453,
31/5355, 31/4166, 31/423, 31/44, C07D 233/70, 233/78,
413/04, 401/04, 491/08

Science Park South, Third Avenue, Harlow, Essex CM19
5AW (GB).

(21) International Application Number: PCT/GB03/00020

(74) Agent: KONDO, Rie; GlaxoSmithKline, CN925.1, 980
Great West Road, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date: 7 January 2003 (07.01.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0200283.0 8 January 2002 (08.01.2002) GB

(71) Applicant (for all designated States except US): GLAXO
GROUP LIMITED [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BROMIDGE,
Steven, Mark [GB/GB]; GlaxoSmithKline, New Frontiers
Science Park South, Third Avenue, Harlow, Essex CM19
5AW (GB). LOVELL, Peter, John [GB/GB]; Glaxo-
SmithKline, New Frontiers Science Park South, Third
Avenue, Harlow, Essex CM19 5AW (GB). GOODACRE,
Caroline [GB/GB]; GlaxoSmithKline, New Frontiers


(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CYCLIC UREA DERIVATIVES WITH 5-HT_{2C} RECEPTOR ACTIVITY



(57) Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof, having 5HT_{2C} receptor activity, are disclosed: wherein a is 0, 1, 2, 3, 4 or 5; b is 1, 2 or 3; Y is nitrogen or carbon; A is oxygen, nitrogen, -CONH-, -NHCO- or together with R² form a benzoxazolone group; R¹ is halogen, C₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkylthio, hydroxy, amino, mono- or di-C₁₋₆alkylamino, nitro, CN, CF₃, OCF₃, aryl, arylC₁₋₆alkyl, arylC₁₋₆alkyloxy or arylC₁₋₆alkylthio; R² is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl or haloC₁₋₆alkoxy; R³ is: (i) -NR⁴R⁵ where R⁴ and R⁵ are independently hydrogen, C₁₋₆alkyl or arylC₁₋₆alkyl; or (ii) an optionally substituted N-linked heterocycle; or (iii) an optionally substituted C-linked heterocycle; ===== is a single bond or a double bond; and X is CH₂ or C=O (when ===== is a single bond) or X is CH (when ===== is a double bond). The preparation of these compounds and their use in therapy, especially for a CNS disorder such as depression or anxiety, are also disclosed.